Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Eccles

Showing results (271-280 of 340) with videos related to

Pageof 34
Sort By:
Breast Cancer Research and Treatment|April 13, 2020
Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohortsDaniele Giardiello, Michael Hauptmann, Ewout W Steyerberg, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsHongyan Li, Christoph Engel, Miguel de la Hoya, et al.
JCO Precision Oncology|September 14, 2019
Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working GroupSarah M Nielsen, Diana M Eccles, Iris L Romero, et al.
Plos One|June 4, 2011
Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association ConsortiumErnest K Amankwah, Qinggang Wang, Joellen M Schildkraut, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 7, 2022
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsHongyan Li, Christoph Engel, Miguel de la Hoya, et al.
NPJ Breast Cancer|February 19, 2025
Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancerReiner Hoppe, Stefan Winter, Wing-Yee Lo, et al.
Journal of Medical Genetics|May 14, 2026
Updated ENIGMA recommendations for reporting germline variants in cancer susceptibility genes and their translation into twenty languagesArcangela De Nicolo, Diana M Eccles, Kirsimari Aaltonen, et al.
The Lancet. Oncology|October 22, 2021
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective studyElizabeth K Bancroft, Elizabeth C Page, Mark N Brook, et al.
Journal of the National Cancer Institute|October 10, 2022
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk LociAmber A DeVries, Joe Dennis, Jonathan P Tyrer, et al.
Breast Cancer Research : BCR|November 30, 2013
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancerSuzanne A Eccles, Eric O Aboagye, Simak Ali, et al.
Pageof 34

Showing results (271-280 of 340) with videos related to

Sort By:
Pageof 34
Breast Cancer Research and Treatment|April 13, 2020
Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohortsDaniele Giardiello, Michael Hauptmann, Ewout W Steyerberg, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsHongyan Li, Christoph Engel, Miguel de la Hoya, et al.
JCO Precision Oncology|September 14, 2019
Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working GroupSarah M Nielsen, Diana M Eccles, Iris L Romero, et al.
Plos One|June 4, 2011
Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association ConsortiumErnest K Amankwah, Qinggang Wang, Joellen M Schildkraut, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 7, 2022
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsHongyan Li, Christoph Engel, Miguel de la Hoya, et al.
NPJ Breast Cancer|February 19, 2025
Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancerReiner Hoppe, Stefan Winter, Wing-Yee Lo, et al.
Journal of Medical Genetics|May 14, 2026
Updated ENIGMA recommendations for reporting germline variants in cancer susceptibility genes and their translation into twenty languagesArcangela De Nicolo, Diana M Eccles, Kirsimari Aaltonen, et al.
The Lancet. Oncology|October 22, 2021
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective studyElizabeth K Bancroft, Elizabeth C Page, Mark N Brook, et al.
Journal of the National Cancer Institute|October 10, 2022
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk LociAmber A DeVries, Joe Dennis, Jonathan P Tyrer, et al.
Breast Cancer Research : BCR|November 30, 2013
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancerSuzanne A Eccles, Eric O Aboagye, Simak Ali, et al.
Pageof 34